1. Home
  2. SHIM vs YARW Comparison

SHIM vs YARW Comparison

Compare SHIM & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shimmick Corporation

SHIM

Shimmick Corporation

HOLD

Current Price

$2.52

Market Cap

128.6M

Sector

N/A

ML Signal

HOLD

Logo Yarrow Bioscience Inc. Common Stock

YARW

Yarrow Bioscience Inc. Common Stock

N/A

Current Price

$19.80

Market Cap

114.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SHIM
YARW
Founded
1990
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
128.6M
114.6M
IPO Year
2023
2017

Fundamental Metrics

Financial Performance
Metric
SHIM
YARW
Price
$2.52
$19.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$7.00
★ $57.00
AVG Volume (30 Days)
★ 130.1K
100.4K
Earning Date
11-12-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 81.95
33.33
EPS
★ N/A
N/A
Revenue
★ $492,844,000.00
N/A
Revenue This Year
$1.41
N/A
Revenue Next Year
$20.36
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 2.63
N/A
52 Week Low
$1.95
$18.16
52 Week High
$6.76
$44.28

Technical Indicators

Market Signals
Indicator
SHIM
YARW
Relative Strength Index (RSI) 28.76 33.61
Support Level $2.45 $18.24
Resistance Level $4.09 $32.89
Average True Range (ATR) 0.20 1.88
MACD -0.05 0.07
Stochastic Oscillator 10.81 19.22

Price Performance

Historical Comparison
SHIM
YARW

About SHIM Shimmick Corporation

Shimmick Corp is engaged in delivering turnkey infrastructure solutions that strengthen critical markets across water, energy, climate resiliency, and sustainable transportation. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains critical infrastructure, including mass transit, bridges, and military infrastructure. The company has one operating and reportable segment: infrastructure solutions. All of its revenue is derived from the United States.

About YARW Yarrow Bioscience Inc. Common Stock

Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.

Share on Social Networks: